UCB (STU:UNC) FFO


STU:UNC UCB SA STU:UNC
89 GF Score
Price €257.90
GF Value €213.09
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is UCB FFO?

FFO (Funds from operations) only applies to REITs.

STU:UNC
89GF Score
UCB SA STU:UNC
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is UCB (STU:UNC) Overvalued in 2026?

Based on GuruFocus' analysis, UCB stock appears to be overvalued. The current stock price of €257.90 is trading 21% above its estimated GF Value™ of €213.09. GuruFocus considers UCB to be Modestly Overvalued.

Key valuation signals for STU:UNC:

  • FFO:
  • GF Value™: €213.09 vs. price of €257.90 (21% above fair value)
  • GF Score™: 89/100 with 2 warning signs

No single metric tells the full story. See the STU:UNC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


UCB Business Description

Address Allee de la Recherche, 60, Brussels, BEL, B-1070
UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome), and Kygevvi (rare mitochondrial disease).
89GF Score

Get the complete analysis for STU:UNC

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€257.90
Price
€213.09
GF Value